Home »
Companies
At the moment we have 34 companies in our incubator program. Check out the companies below and see also our alumni companies here.
AarogyaAI
AarogyaAI’s vision is to make precision diagnosis for antimicrobial resistance accessible at the point of care by harnessing the powers of genomics and artificial intelligence. The aim is to reduce the incidence and spread of antimicrobial-resistant infections and stay one step ahead of the bugs! AI helps unearth future drug resistance patterns to preemptively plan actions and combat the next pandemic.
-
- Founding year:
2019
-
- Development phase:
Beta-testing
-
- Funding stage:
Seed
-
- Website:
-
- Contact person info:
avlokita(at)aarogya.ai
-
- Team members:
25
Ai2Ai Oy
PALL0 by Ai2Ai is a sensor-packed interactive ball with AI and unlimited apps. The product boosts physical and social activities for wellness seekers and reduces screen time.
-
- Founding year:
2017
-
- Development phase:
Beta-testing
-
- Funding stage:
Seed
-
- Website:
-
- Contact person info:
henrik(at)ai2ai.fi
-
- Team members:
8
AnalysisMode
No more trial-and-error research. AnalysisMode offers online Laboratory Environment Simulators, helping scientists to design experiments and predict failure. From cell-culture simulation to OMICS predictors, the scientists using AnalysisMode reduce their research time, being able to perform a 1-week experiment in just 1-hour, saving 700 hours per year and yielding 5x more discoveries. AnalysisMode tailors its simulators to each customer.
-
- Founding year:
2020
-
- Development phase:
Market-ready
-
- Funding stage:
Pre-seed
-
- Website:
-
- Contact person info:
tiago(at)fibo.io
-
- Team members:
12
-
- Article:
Read an article about AnalysisMode.
Auxcuro
Auxcuro provides technical solutions for healthcare clinicians by integrating care delivery information in real-time. The company’s technical platform is an intuitive, customisable, predictive smart data integration repository that supports Frontline Healthcare Workers.
-
- Founding year:
2022
-
- Development phase:
Proof-of-Concept
-
- Funding stage:
Pre-seed
-
- Website:
-
- Contact person info:
gran.ben9(at)gmail.com
-
- Team members:
2
Cardiolyse
Cardiolyse provides a chronic and post-discharge cardiovascular disease patient monitoring platform with medical-grade AI heart health analytics (CE class 2a, 19 arrhythmias) that enables remote vital sign monitoring and personalized patient reports for early diagnostics and better care.
-
- Founding year:
2016
-
- Development phase:
Market-ready
-
- Funding stage:
Late-seed
-
- Website:
-
- Contact person info:
anna.starynska(at)cardiolyse.com
-
- Team members:
11
Cardiomtec
Cardiomtec is a Finnish 2020 founded corporation holding more than 20 years of experience of developing medical devices. Cardiomtec specializes in developing applications and portable devices for wellbeing technology. Cardiomtec products are affordable, small and reliable. With Cardiomtec devices one can measure and evaluate cardiac function of an individual at home environment, data is uploaded to a cloud server from where a medical doctor can review it with web-portal.
-
- Founding year:
2019
-
- Development phase:
Prototype
-
- Funding stage:
Pre-seed
-
- Website:
-
- Contact person info:
mikko.kaski(at)cardiomtec.fi
-
- Team members:
3
-
- Article:
Read an article about Cardiomtec.
ClickPET
ClickPET offers technical solutions for simplifying the production of disease specific biomolecule-based radiopharmaceuticals for positron emission tomography (PET) for aiding patient selection, cancer staging and disease follow-up by diagnostic imaging. The company's technology enables the speeding-up of new radiotracer development facilitating the discovery of new diagnostic methods for personalized medicine.
-
- Founding year:
R2B project started in January 2022
-
- Development phase:
Prototype
-
- Funding stage:
Pre-seed in 2024
-
- Website:
-
-
- Contact person info:
raymond.li(at)helsinki.fi
-
- Team members:
7
CorFlux
CorFlux aims to be the world’s leading analyzing software for estimating the risk of aortic aneurysm rupture. The current clinical method does not take into account other influencing elements than the aortic diameter in the risk evaluation. However, a high number of aortic ruptures appear before the diameter reaches the limit for surgery. CorFlux decision-making support allows physicians to identify high-risk aneurysm patients more easily, leading to life savings.
-
- Founding year:
R2B project started August 2022
-
- Development phase:
Proof-of-Concept
-
- Funding stage:
Seed
-
- Website:
-
- Contact person info:
tero.puustinen(at)uef.fi
-
- Team members:
7
Corle Oy
Corle is developing a small wireless medical device for the diagnostic and monitoring purposes of sleep apnea. The patented solution is a non-invasive optical sensor for continuous medical grade health data collection from the earlobe, sending the data via Bluetooth to a mobile phone application for analysis and sharing.
-
- Founding year:
2017
-
- Development phase:
Prototype
-
- Funding stage:
Seed in 2022
-
- Website:
-
- Contact person info:
peik(at)corle.fi
-
- Team members:
2
CurifyLabs
CurifyLabs is set to transform personalized drug manufacturing through its digital and automated TailoredCure technology. We offer a Medicine as a Service concept for pharmacies, hospital pharmacies and veterinarians which saves time, delivers better and sustainable future treatments to pets and humans.
-
- Founding year:
2021
-
- Development phase:
Beta-testing
-
- Funding stage:
A round late 2022
-
- Website:
-
- Contact person info:
charlotta(at)curify.io
-
- Team members:
7
EpiHeart
EpiHeart is a young medical device company focused on enabling Cardiac Micrograft Therapy™, an adjuvant therapy administered during cardiac interventions such as coronary artery bypass grafting surgery. Cardiac Micrograft Therapy™ is a novel therapy for treating ischemic injury and consequent ischemic scars and heart failures. The company is focused on the development and commercialization of medical device packages to enable the therapy and it aims to drive the therapy into mainstream clinical use. The first-in-man clinical trial has already been completed in academic setting. The company is a spin-out from the University of Helsinki and the HUS Helsinki University Hospital.
-
- Founding year:
2019
-
- Development phase:
Early clinical stage
-
- Funding stage:
A-round
-
- Website:
-
- Contact person info:
kai.kronstrom(at)epiheart.com
-
- Team members:
4
-
- Article:
Read an article about EpiHeart.
EsaDres
AarogyaAI’s vision is to make precision diagnosis for antimicrobial resistance accessible at the point of care by harnessing the powers of genomics and artificial intelligence. The aim is to reduce the incidence and spread of antimicrobial-resistant infections and stay one step ahead of the bugs! AI helps unearth future drug resistance patterns to preemptively plan actions and combat the next pandemic.
-
- Founding year:
2019
-
- Development phase:
Beta-testing
-
- Funding stage:
Seed
-
- Website:
-
- Contact person info:
avlokita(at)aarogya.ai
-
- Team members:
25
Evexia
Evexia encourages patient-oriented healthcare through building a new digital solution for cancer care. Alas, no solution exists in helping doctors determine objectively the physical condition of the patient. Evexia’s mobile application, data analysis and clinical dashboard allows doctors to make better and more objective care decisions for patients and thus make cancer care better for all involved.
-
- Founding year:
2020
-
- Development phase:
Prototype
-
- Funding stage:
Pre-seed
-
- Website:
-
- Contact person info:
team(at)evexia.fi
-
- Team members:
5
-
- Article:
Read an article about Evexia.
Fepod Oy
Fepod Oy Ltd is developing and commercialising cutting edge IVD technology platform that enables measuring the real blood concentration of pain medicine and other markers directly from a drop of blood at the point-of-care. Our technology provides a fast, simple, and relatively painless sampling process with quick test results using a mobile phone, portable potentiostat and mass-producible & disposable sampling sensors.
-
- Founding year:
2022
-
- Development phase:
Piloting
-
- Funding stage:
Seed
-
- Website:
-
- Contact person info:
jussi(at)fepod.com
-
- Team members:
6
-
- Article:
Read an article about Fepod.
Finnadvance
Finnadvance is bridging the gap between in-vitro and in-vivo research with its microfluidic organ-on-chips for pharmaceutical drug research and development. With industry leading high throughput microphysiological culture platforms, complex in vivo biomechanical cues are mimicked on the in vitro cultures.
-
- Founding year:
2019
-
- Development phase:
Market-ready
-
- Funding stage:
A round
-
- Website:
-
- Contact person info:
science(at)finnadvance.com
-
- Team members:
18
-
- Article:
Read an article about Finnadvance.
Flux Polymers
Flux Polymers produces a hydrophilic polymer that can be spray or dip coated onto plastic surfaces and permanently linked by UV-irradiation. The patented coating prevents the attachment and growth of bacteria. The antibacterial effect of the coating is based on a purely physical effect, so that no toxic substances are released that could cause resistance in bacteria. The process is fast, cost efficient and not detrimental to the used material.
-
- Founding year:
2017
-
- Development phase:
Market-ready
-
- Funding stage:
Seed
-
- Website:
-
- Contact person info:
a.luxenhofer(at)flux-polymers.com
-
- Team members:
2
-
- Article:
Read an article about Flux Polymers.
HATO Medical Technologies
HATO Medical Technologies empowers healthcare professionals to make prompt decisions, accurate triage, correct referrals, and save lives and valuable resources by getting it right the first time. The company utilises artificial intelligence to enhance the accuracy and efficiency of electrocardiogram (ECG) interpretation. By providing innovative solutions, HATO aims to support healthcare professionals, especially those without specialised cardiology expertise, in diagnosing and treating cardiovascular diseases more effectively.
-
- Founding year:
2020
-
- Development phase:
Beta-testing
-
- Funding stage:
Pre-seed
-
- Website:
-
- Contact person info:
sy(at)hatomedicaltechnologies.com
-
- Team members:
6
Hoivita
Hoivita Oy creates remote health monitoring solutions to home care service providers, assisted living facilities and health and wellbeing service providers for the elderly to extend their stay and ensure safe living at home. The company's completely contactless sensor solutions can easily be installed in minutes. They can be automatically connected to the data network for monitoring and analysis to begin immediately. The health care service providers can easily view the situation of the elderly and view their progress in the web service. The company consists of international experts who graduated from LUT University, specialists from the homecare sector and long-term entrepreneurs.
-
- Founding year:
2022
-
- Development phase:
Market-ready
-
- Funding stage:
Seed
-
- Website:
-
- Contact person info:
abhishek.jayaprakash(at)hoivita.com
-
- Team members:
7
-
- Article:
Read an article about Hoivita.
Karsa Oy
The Karsa chemical analysis platform eliminates laborious workflows for the analysis of small molecules. The company wants to bring this approach to the IVD market with analysis of bodily fluids.
-
- Founding year:
2016
-
- Development phase:
Proof-of-concept/prototype ready
-
- Funding stage:
Seed
-
- Website:
-
- Contact person info:
karsa(at)karsa.fi
-
- Team members:
15
-
- Article:
Read an article about Karsa.
Lapsi Health B.V.
Lapsi Health is developing the new generation of digital biomarkers based on auscultatory sound. The data used as a biomarker has to be quantifiable and objective and the company’s novel technology greatly enhances its usage in medicine, relating it to the health-disease process for prognostic, diagnostic and therapeutic purposes.
-
- Founding year:
2022
-
- Development phase:
Prototype/beta testing
-
- Funding stage:
Pre-seed/Seed
-
- Website:
-
- Contact person info:
info(at)lapsihealth.com
-
- Team members:
6
-
- Article:
Read an article about Lapsi Health.
Maculaser
Maculaser develops novel medical technology for treatment of common retinal diseases, including diabetic macular edema and dry age-related macular degeneration. The core of the company’s innovation is the precise temperature control of the macula during non-damaging laser treatments; a potential game changer in the practice how retinal diseases, with over 200B EUR direct health care costs, are being treated in the future.
-
- Founding year:
2020
-
- Development phase:
Beta-testing
-
- Funding:
Seed / A round
-
- Website:
-
- Contact person info:
jani.tirronen(at)maculaser.com
-
- Team members:
5
-
- Article:
Read an article about Maculaser.
MedicubeX
MedicubeX is developing a self-check station with several disruptive health measurements and remote appointment technology. The measurement station allows for the individual the measurement of their own vital signs and novel noninvasive cardiovascular risk factors. End users are not only patients, but also healthy individuals looking for their personal health status and early signs of potential diseases. The station’s soundproofing maintains privacy while cutting-edge sterilization technology keeps the station clear of microbes and viruses.
-
- Founding year:
-
- Development phase:
-
- Funding stage:
-
- Website:
-
- Contact person info:
-
- Team members:
-
- Article:
2020Beta-testingSeedvili.kostamo(at)medicubex.fi7Read an article about MedicubeX.
Mediverse
Mediverse functions as a crucial component of the conventional healthcare system, operating as a telemedicine platform that incorporates advanced technology and intelligent biosensors. As a result, patients can receive remote medical consultations, diagnoses, and treatments in a timely manner, irrespective of their location.
-
- Founding year:
2023
-
- Development phase:
Proof-of-Concept
-
- Funding stage:
Pre-seed
-
- Website:
-
- Contact person info:
mahmood(at)mediversefi.com
-
- Team members:
5
Mind’s Eye
AarogyaAI’s vision is to make precision diagnosis for antimicrobial resistance accessible at the point of care by harnessing the powers of genomics and artificial intelligence. The aim is to reduce the incidence and spread of antimicrobial-resistant infections and stay one step ahead of the bugs! AI helps unearth future drug resistance patterns to preemptively plan actions and combat the next pandemic.
-
- Founding year:
2019
-
- Development phase:
Beta-testing
-
- Funding stage:
Seed
-
- Website:
-
- Contact person info:
avlokita(at)aarogya.ai
-
- Team members:
25
Moncyte
Efficient lowering of blood cholesterol is pivotal in reducing the risk for heart attack and stroke, the most frequent causes of death globally. Different cholesterol-lowering drugs are available, but it is difficult to find an optimal treatment strategy for each person, resulting in suboptimal treatment and an increased risk for heart attack and stroke for many patients. The Moncyte analysis tool sheds light on why individuals respond differently to cholesterol-lowering medication. This will enable novel personalized treatment strategies, helping more patients to achieve their blood cholesterol target levels and reducing cardiovascular morbidity and mortality.
-
- Founding year:
Currently R2B project that started 1 July, 2021
-
- Development phase:
Proof-of-concept
-
- Funding stage:
Pre-seed in 2023
-
- Website:
-
- Contact person info:
tamara.alagirova(at)helsinki.fi
-
- Team members:
4
-
- Article:
Read an article about Moncyte.
NADMED Oy
The biology and key role of NAD molecules in human metabolism has been well known for decades, but measuring them has been devilishly difficult. NADMED has now brought to market an accurate, fast, scalable, and well protected method to do just that. The assay enables research in large human cohorts, leading to a rapidly increasing number of clinical applications. NADMED already services clinical practitioners, researchers and drug development companies.
-
- Founding year:
2022
-
- Development phase:
Market-ready
-
- Funding stage:
Seed
-
- Website:
-
- Contact person info:
jari.narhi(at)nadmed.com
-
- Team members:
8
-
- Article:
Read an article about NADMED.
Natal Mind
AarogyaAI’s vision is to make precision diagnosis for antimicrobial resistance accessible at the point of care by harnessing the powers of genomics and artificial intelligence. The aim is to reduce the incidence and spread of antimicrobial-resistant infections and stay one step ahead of the bugs! AI helps unearth future drug resistance patterns to preemptively plan actions and combat the next pandemic.
-
- Founding year:
2019
-
- Development phase:
Beta-testing
-
- Funding stage:
Seed
-
- Website:
-
- Contact person info:
avlokita(at)aarogya.ai
-
- Team members:
25
NE Device SW
AarogyaAI’s vision is to make precision diagnosis for antimicrobial resistance accessible at the point of care by harnessing the powers of genomics and artificial intelligence. The aim is to reduce the incidence and spread of antimicrobial-resistant infections and stay one step ahead of the bugs! AI helps unearth future drug resistance patterns to preemptively plan actions and combat the next pandemic.
-
- Founding year:
2019
-
- Development phase:
Beta-testing
-
- Funding stage:
Seed
-
- Website:
-
- Contact person info:
avlokita(at)aarogya.ai
-
- Team members:
25
Nordic Fit Mama
Nordic Fit Mama is a Finnish company that offers online wellness training for mothers. An award winning, 6-week Post Natal Program helps women to recover post-baby body in a safe way with the support of trained professionals. Nordic Fit Mama also offers a program for pregnant women and another one for more intensive training. All exercises are medically approved and recommended by gynecologists, midwives and physiotherapists. In September 2020 Nordic Fit Mama launched its first program for women in menopause.
-
- Founding year:
2019
-
- Development phase:
Scale up
-
- Funding stage:
Pre-seed
-
- Website:
-
- Contact person info:
riina(at)nordicfitmama.fi
-
- Team members:
3
-
- Article:
Read an article about Nordic Fit Mama.
Olo (by Nature Solutions Oy)
Olo empowers mindful exploration of self, community, and nature through personalized digital experiential learning that incorporates immersive listening and embodiment practice with real-time biofeedback and community support in a mobile app experience. Built on the foundation of neuroscience research and AI-powered technology, Olo’s app uniquely responds to the prolific mental health and stress management needs of each individual user.
-
- Founding year:
2018
-
- Development phase:
Proof-of-concept
-
- Funding stage:
Pre-seed
-
- Website:
-
- Contact person info:
markus(at)naturesolutions.fi
-
- Team members:
5
Otos
AarogyaAI’s vision is to make precision diagnosis for antimicrobial resistance accessible at the point of care by harnessing the powers of genomics and artificial intelligence. The aim is to reduce the incidence and spread of antimicrobial-resistant infections and stay one step ahead of the bugs! AI helps unearth future drug resistance patterns to preemptively plan actions and combat the next pandemic.
-
- Founding year:
2019
-
- Development phase:
Beta-testing
-
- Funding stage:
Seed
-
- Website:
-
- Contact person info:
avlokita(at)aarogya.ai
-
- Team members:
25
Probiont Oy
Probiont is developing personalized solutions for cancer immunotherapy efficacy testing. Our technology is purposed to enable rapid screening of cancer drugs used in immunotherapy, for early identification of effective treatment strategies for individual patients.
-
- Founding year:
2021
-
- Development phase:
Prototype
-
- Funding stage:
Pre-seed
-
- Website:
-
- Contact person info:
benedek.poor(at)probiont.fi
-
- Team members:
3
R2therapies Oy
R2therapies Oy has discovered a novel and scientifically surprising blood-based biomarker to identify people at risk of developing dementia. The company aims to to develop an in-vitro diagnostic method compatible with primary healthcare for dementia-risk screening.
-
- Founding year:
2022
-
- Development phase:
Clinical validation
-
- Funding stage:
Pre-seed
-
- Website:
-
-
- Contact person info:
ilkka.fagerlund(at)gmail.com
-
- Team members:
4
RoboMed
AarogyaAI’s vision is to make precision diagnosis for antimicrobial resistance accessible at the point of care by harnessing the powers of genomics and artificial intelligence. The aim is to reduce the incidence and spread of antimicrobial-resistant infections and stay one step ahead of the bugs! AI helps unearth future drug resistance patterns to preemptively plan actions and combat the next pandemic.
-
- Founding year:
2019
-
- Development phase:
Beta-testing
-
- Funding stage:
Seed
-
- Website:
-
- Contact person info:
avlokita(at)aarogya.ai
-
- Team members:
25
Sartar Therapeutics
Sartar Therapeutics revolutionizes sarcoma therapy. There is an urgent clinical need to find efficacious sarcoma therapies. Sartar
Therapeutics is a preclinical stage biotech company that will meet the need by developing precision medicine products to treat rare cancers. The first product candidate SAR001 is based on Sartar’s repurposed, proprietary reformulated anagrelide. SAR001 is a controlled-release anagrelide product that targets PDE3A protein that is highly expressed in sarcomas such as gastrointestinal stromal tumor, liposarcoma and other soft tissue sarcomas.
-
- Founding year:
2016
-
- Development phase:
Pre clinical stage
-
- Funding stage:
A round completed in Q4/2020
-
- Website:
-
- Contact person info:
katja.ivanitskiy(at)sartartherapeutics.com
-
- Team members:
3
-
- Article:
Read an article about Sartar Therapeutics.
SCellex
SCellex develops novel solutions for spatial single cell gene sequencing analyses with patented coloured microbeads on picowell arrays. The method works in various applications and is suitable both for tissue cryosections and cell suspensions, allowing also functional high throughput cell assays and single cell cultures in picowells. The method helps biomedical researchers to discover the locations, roles and interactions of different cell types both in healthy tissues and diseases, and to explore their key marker genes as potential drug targets.
-
- Founding year:
2018
-
- Development phase:
Beta-testing
-
- Funding stage:
Seed
-
- Website:
-
- Contact person info:
paivi.saavalainen(at)scellex.com
-
- Team members:
8
-
- Article:
Read an article about SCellex.
SeeTrue Technologies
AarogyaAI’s vision is to make precision diagnosis for antimicrobial resistance accessible at the point of care by harnessing the powers of genomics and artificial intelligence. The aim is to reduce the incidence and spread of antimicrobial-resistant infections and stay one step ahead of the bugs! AI helps unearth future drug resistance patterns to preemptively plan actions and combat the next pandemic.
-
- Founding year:
2019
-
- Development phase:
Beta-testing
-
- Funding stage:
Seed
-
- Website:
-
- Contact person info:
avlokita(at)aarogya.ai
-
- Team members:
25
SIR Analytics
SIR Analytics brings 21st-century technology to blind people around the globe. Using the company's smart cane, blind and visually impaired people can independently move around without unnecessary risks of injuries or getting lost.
-
- Founding year:
2018
-
- Development phase:
Beta testing
-
- Funding stage:
Pre-seed
-
- Website:
-
- Contact person info:
albert.manninen(at)siranalytics.com
-
- Team members:
3
SOENIA
SOENIAⓇ by BrainCare is a Tampere University of Technology spin-off company founded in 2013. The mission is to offer remote long-term monitoring solutions to improve the quality of life of neurological patients with a special focus on epilepsy. The company offers a novel mobile application and supporting solutions for digital symptom tracking to better monitor and understand the conditions of each patient. Both the app and the implant send their data directly to the patient’s doctor via secure cloud platform, SOENIA® Cloud. Patient-generated data from the SOENIA® Medical Diary app is shown alongside the EEG activity, which helps doctors plan and provide better treatments. CE-marked SOENIA® Medical Diary application and SOENIA® Cloud were piloted and evaluated in clinical trials at the Tampere University Hospital.
-
- Founding year:
2016
-
- Development phase:
Proof-of-concept / Prototype
-
- Funding stage:
Seed
-
- Website:
-
- Contact person info:
katrina(at)soenia.com
-
- Team members:
4
-
- Article:
Read an article about SOENIA.
Solid-IO
AarogyaAI’s vision is to make precision diagnosis for antimicrobial resistance accessible at the point of care by harnessing the powers of genomics and artificial intelligence. The aim is to reduce the incidence and spread of antimicrobial-resistant infections and stay one step ahead of the bugs! AI helps unearth future drug resistance patterns to preemptively plan actions and combat the next pandemic.
-
- Founding year:
2019
-
- Development phase:
Beta-testing
-
- Funding stage:
Seed
-
- Website:
-
- Contact person info:
avlokita(at)aarogya.ai
-
- Team members:
25
Sonai Health Oy
Sonai Health develops a new solution for heart diagnosis, utilising patented sensor solution, cloud service and machine learning.
-
- Founding year:
2021
-
- Development phase:
Prototype
-
- Funding stage:
Pre-seed
-
- Website:
-
- Contact person info:
jyri.seppa(at)sonai.fi
-
- Team members:
4
-
- Article:
Read an article about Sonai Health Oy.
Surgerix
AarogyaAI’s vision is to make precision diagnosis for antimicrobial resistance accessible at the point of care by harnessing the powers of genomics and artificial intelligence. The aim is to reduce the incidence and spread of antimicrobial-resistant infections and stay one step ahead of the bugs! AI helps unearth future drug resistance patterns to preemptively plan actions and combat the next pandemic.
-
- Founding year:
2019
-
- Development phase:
Beta-testing
-
- Funding stage:
Seed
-
- Website:
-
- Contact person info:
avlokita(at)aarogya.ai
-
- Team members:
25
Uute Scientific
Uute Scientific drives for “Life without immune-mediated diseases”, such as diabetes 1, allergies and asthma. These immune-mediated diseases are caused by our modern and urban lifestyle. Our move away from nature with its microbial diversity has made our immune system weaker. Uute has patent pending substance, which brings that natural microbial diversity back to people and help them in the development of a strong immune system. Uute will be available to people through consumer product companies.
-
- Founding year:
2019
-
- Development phase:
Market-ready
-
- Funding stage:
Seed
-
- Website:
-
- Contact person info:
kari.sinivuori(at)uutescientific.com
-
- Team members:
7
-
- Article:
Read an article about Uute Scientific.
Our alumni
The following companies have participated in our incubator program.
DataSolu
DataSolu is a life sciences technology company helping pharma companies to speed up their preclinical drug development by revealing and predicting hidden heart diseases and failures with assistance of biomimicry and AI. The company’s technologies benefit drug development, personalized drug screening approaches and toxicological validation to eliminate compounds with undesirable cardiac effects.
Healthzilla
Healthzilla is a wellness focused technology company, developing solutions for consumers and businesses. The core technology is the ability to gather and analyze stress and habit data at scale. The company is developing a SaaS dashboard solution for industries such as insurance, fitness, and workplace wellness.
Jasmine PRO
Drug developers aspire to create drugs that home into their target cells without causing toxicity and adverse effects. Polymers are critical enablers of advanced drug delivery systems, but the current polymers have suboptimal characteristics and technical challenges. Jasmine PRO has designed a novel enhanced drug delivery system based on jasmine lactone polymer. The platform will enable drug companies to design and develop safer medicines for various indications such as oncology and immunology.
Knewborn.AI
Knewborn.AI brings predictability and improved results to infertility treatments through the power of machine learning.
Medified
Medified is transforming mental health treatments with data-driven monitoring software. Software develops a dynamic and secure connection between patients and healthcare professionals to create a more extensive overview of the patient personal recovery process. The company’s SaaS is designed to improve the intensity of mental health treatment and enable digital healthcare services. Mindler acquired Medified.
Phonolyser
Phonolyser is dedicated to lightening the burden of people dealing with Congenital Heart Disease (CHD). The company provides a smart heart sound analyzer device combining AI, doppler, and sound effects to accurately diagnose CHD. The diagnosis takes only two minutes, saving lives around the world and making an impact on the health of so many.
SciAR
SciAR is changing the life science industry by bringing next-generation digital tools to every scientist in every laboratory. The main product is a Holistic Laboratory Management Software composed of two parts. First is Augmented Reality Workflow called Sciar Co-Pilot that helps to show the instructions in an easy way and automated checks using the AR-headset camera prevent costly errors. The second part is Sciar Vault, a secure cloud platform that can be used to manage workflows, design and modify protocols and access documentation. The combination of these services makes laboratory processes faster, prevents errors in these processes and makes the Good Manufacturing Practices (GMP) compliance easier than ever before.
Trialwell
Trialwell is a digital platform utilising AI that helps to raise awareness of clinical trials and studies that are non-pharmaceutical with a focus on health and wellbeing, whilst providing a cost effective recruitment service for researchers and sponsors. Our aim is to help as many people as possible know that these types of research projects are open for them to join, which could also be of value and benefit according to their personal health profile.
VEIL.AI
VEIL.AI is a spin-out from FIMM (Institute for Molecular Medicine Finland). The company wants to enable discoveries for better health; it enables utilization of sensitive health data for new discoveries and better decision making in healthcare. VEIL.AI specializes in health data anonymization services and synthetic data. The unique technology helps healthcare actors to utilize sensitive data in ways that were not possible before – combine, analyze and share sensitive data more securely, efficiently and with richer quality.
